BRPI0811265A2 - Tratamento de sinucleinopatias - Google Patents

Tratamento de sinucleinopatias

Info

Publication number: BRPI0811265A2
Authority: BR; Brazil
Prior art keywords: synucleinopathies; treatment
Prior art date: 2007-05-16

Application number

BRPI0811265-7A2A

Other languages

English (en)

Inventor

Michael Schlossmacher

Valerie Cullen

Lamya Shihabuddin

Seng H Cheng

Original Assignee

Brigham & Womens Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-16

Filing date

2008-05-16

Publication date

2014-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40122277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811265(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-16 Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital

2014-09-30 Publication of BRPI0811265A2 publication Critical patent/BRPI0811265A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22041—Cathepsin F (3.4.22.41)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/23—Aspartic endopeptidases (3.4.23)
- C12Y304/23005—Cathepsin D (3.4.23.5)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Marine Sciences & Fisheries (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Anesthesiology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0811265-7A2A 2007-05-16 2008-05-16 Tratamento de sinucleinopatias BRPI0811265A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US93046207P	2007-05-16	2007-05-16
US92955407P	2007-07-03	2007-07-03
PCT/US2008/064017 WO2008144591A2 (en)	2007-05-16	2008-05-16	Treatment of synucleinopathies

Publications (1)

Publication Number	Publication Date
BRPI0811265A2 true BRPI0811265A2 (pt)	2014-09-30

Family

ID=40122277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0811265-7A2A BRPI0811265A2 (pt)	2007-05-16	2008-05-16	Tratamento de sinucleinopatias

Country Status (18)

Country	Link
US (4)	US8454954B2 (pt)
EP (2)	EP2154969B1 (pt)
JP (4)	JP5291093B2 (pt)
CN (2)	CN101754682B (pt)
AU (1)	AU2008254774B2 (pt)
BR (1)	BRPI0811265A2 (pt)
CA (1)	CA2684946C (pt)
CY (1)	CY1117312T1 (pt)
DK (1)	DK2154969T3 (pt)
ES (1)	ES2559859T3 (pt)
HK (2)	HK1141406A1 (pt)
HR (1)	HRP20151409T1 (pt)
HU (1)	HUE027278T2 (pt)
MX (1)	MX353727B (pt)
PL (1)	PL2154969T3 (pt)
PT (1)	PT2154969E (pt)
SI (1)	SI2154969T1 (pt)
WO (1)	WO2008144591A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101754682B (zh)	2007-05-16	2014-11-12	布里格姆妇女医院	突触核蛋白病的治疗
US20110064721A1 (en) *	2007-07-12	2011-03-17	The Uab Research Foundation	Cathepsin-d neuroprotection
GB201011420D0 (en) *	2010-07-06	2010-08-18	United Arab Emirates Universit	Method for diagnosis
US9290759B2 (en) *	2010-08-25	2016-03-22	The Trustees Of Columbia University In The City Of New York	Optimized miRNA constructs
DK2649075T3 (en)	2010-12-08	2018-07-30	Us Health	SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS
DK2691529T3 (da)	2011-03-31	2019-09-23	Univ Iowa Res Found	AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse
EP2533051A1 (en)	2011-06-06	2012-12-12	Centogene GmbH	Method for the diagnosis of Gaucher's disease
IN2014KN02672A (pt) *	2012-05-18	2015-05-08	Univ Iowa Res Found
KR20150079751A (ko) *	2012-11-05	2015-07-08	젠자임 코포레이션	단백질병을 치료하기 위한 조성물 및 방법
WO2014078522A1 (en)	2012-11-14	2014-05-22	Ohio State Innovation Foundation	Materials and methods useful for treating glioblastoma
MX2016005631A (es) *	2013-11-21	2016-07-14	Hoffmann La Roche	Anticuerpos anti-alfa-sinucleina y metodos de uso.
WO2016025533A2 (en) *	2014-08-11	2016-02-18	Whitehead Institute For Biomedical Research	Compositions and methods for treating synucleinopathies
US10724096B2 (en) *	2014-09-05	2020-07-28	Population Bio, Inc.	Methods and compositions for inhibiting and treating neurological conditions
WO2016164474A1 (en) *	2015-04-06	2016-10-13	The Trustees Of Columbia University In The City Of New York	Predictive value of combined genetic enzymatic and lipidomic data in disease risk for lewy body disease
AU2016256895B2 (en)	2015-05-07	2022-05-26	Takeda Pharmaceutical Company Limited	Glucocerebrosidase gene therapy for parkinson's disease
GB201512203D0 (en) *	2015-07-13	2015-08-19	Lundbeck & Co As H	Agents,uses and methods
CN116196410A (zh) *	2015-10-28	2023-06-02	宾夕法尼亚州大学信托人	鞘内施用腺伴随病毒载体用于基因治疗
EP3264092A1 (en) *	2016-07-01	2018-01-03	Centogene AG	Use of lyso-gb1 as druggable target
KR102623819B1 (ko)	2017-03-27	2024-01-10	체이스 테라퓨틱스 코포레이션	시누클레인병변을 치료하기 위한 조성물 및 방법
CN112481269A (zh)	2017-10-03	2021-03-12	普利维尔治疗公司	用于溶酶体障碍的基因疗法
JP2020537542A (ja)	2017-10-03	2020-12-24	プリベイルセラピューティクス, インコーポレーテッドPrevail Therapeutics, Inc.	ライソゾーム病の遺伝子治療
JP7254815B2 (ja)	2017-10-03	2023-04-10	プリベイルセラピューティクス，インコーポレーテッド	ライソゾーム病の遺伝子治療
WO2019138057A1 (en) *	2018-01-12	2019-07-18	Roche Innovation Center Copenhagen A/S	Alpha-synuclein antisense oligonucleotides and uses thereof
EP3787748A1 (en)	2018-05-01	2021-03-10	OrfoNeuro ApS	Treatment of neuronal ceroid lipofuscinosis
CN113728230A (zh) *	2018-12-05	2021-11-30	华盛顿大学	检测、预防、逆转和治疗神经系统疾病的方法
CA3128875A1 (en)	2019-02-04	2020-08-13	Freeline Therapeutics Limited	Polynucleotides
EP3953378A1 (en)	2019-04-10	2022-02-16	Prevail Therapeutics, Inc.	Gene therapies for lysosomal disorders
CA3148090A1 (en)	2019-07-24	2021-01-28	Stealth Biotherapeutics Inc.	The peptidomimetic compound (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-i-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases
US20230103407A1 (en) *	2020-03-10	2023-04-06	University Of Cincinnati	Materials and methods for the treatment of gaucher disease
KR20230042513A (ko)	2020-07-29	2023-03-28	프리라인 테라퓨틱스 리미티드	폴리펩티드

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5672344A (en)	1987-12-30	1997-09-30	The Regents Of The University Of Michigan	Viral-mediated gene transfer system
US20020168750A1 (en)	1988-12-23	2002-11-14	James Rasmussen	Enzymatically active recombinant glucocerebrosidase
EP0500799B1 (en)	1989-11-16	1998-01-14	Duke University	Particle mediated transformation of animal skin tissue cells
US5858784A (en)	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
TW360548B (en)	1993-04-08	1999-06-11	Powderject Res Ltd	Products for therapeutic use
JP3532566B2 (ja)	1993-06-24	2004-05-31	エル．グラハム，フランク	遺伝子治療のためのアデノウイルスベクター
US5571787A (en) *	1993-07-30	1996-11-05	Myelos Corporation	Prosaposin as a neurotrophic factor
ATE437232T1 (de)	1993-10-25	2009-08-15	Canji Inc	Rekombinanter adenoviren-vektor und verfahren zur verwendung
ATE260980T1 (de)	1993-11-09	2004-03-15	Targeted Genetics Corp	Die erzielung hoher titer des rekombinanten aav- vektors
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
EP0755454B1 (en)	1994-04-13	2008-02-13	The Rockefeller University	Aav-mediated delivery of dna to cells of the nervous system
US6042820A (en)	1996-12-20	2000-03-28	Connaught Laboratories Limited	Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en)	1998-04-16	2002-10-29	John Wayne Cancer Institute	DNA vaccine and methods for its use
US6544785B1 (en)	1998-09-14	2003-04-08	Mount Sinai School Of Medicine Of New York University	Helper-free rescue of recombinant negative strand RNA viruses
WO2000025138A2 (en)	1998-10-23	2000-05-04	Roger Nitsch	Methods of diagnosing or prognosing alzheimer's disease
DE60042338D1 (de)	1999-10-04	2009-07-16	Univ New Jersey Med	TAR RNA bindende Peptide
US6667174B2 (en)	2000-09-18	2003-12-23	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
TW200918046A (en)	2002-04-03	2009-05-01	Novartis Ag	Indolylmaleimide derivatives
EP1638605B1 (en) *	2003-06-20	2014-01-08	Raptor Pharmaceutical, Inc.	Delivery of therapeutic compounds to the brain and other tissues
US20050208090A1 (en) *	2004-03-18	2005-09-22	Medtronic, Inc.	Methods and systems for treatment of neurological diseases of the central nervous system
KR20080033242A (ko) *	2005-06-08	2008-04-16	아미쿠스 세라퓨틱스, 인코포레이티드	리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법
ES2679994T3 (es) *	2005-08-11	2018-09-03	Arpi Matossian-Rogers	Péptidos relacionados con TCR-V-BETA para el tratamiento y diagnóstico de enfermedad autoinmune
AR059089A1 (es)	2006-01-20	2008-03-12	Genzyme Corp	Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2387845T3 (es) *	2006-06-23	2012-10-02	Amicus Therapeutics, Inc.	Método para el tratamiento de trastornos neurológicos mejorando la actividad de beta-glucocerebrosidasa
CN101754682B (zh) *	2007-05-16	2014-11-12	布里格姆妇女医院	突触核蛋白病的治疗
US20110064721A1 (en) *	2007-07-12	2011-03-17	The Uab Research Foundation	Cathepsin-d neuroprotection

2008
- 2008-05-16 CN CN200880025136.0A patent/CN101754682B/zh not_active Expired - Fee Related
- 2008-05-16 CN CN201410524803.7A patent/CN104383556B/zh not_active Expired - Fee Related
- 2008-05-16 BR BRPI0811265-7A2A patent/BRPI0811265A2/pt not_active IP Right Cessation
- 2008-05-16 EP EP08755799.7A patent/EP2154969B1/en not_active Revoked
- 2008-05-16 WO PCT/US2008/064017 patent/WO2008144591A2/en active Application Filing
- 2008-05-16 CA CA2684946A patent/CA2684946C/en not_active Expired - Fee Related
- 2008-05-16 PT PT87557997T patent/PT2154969E/pt unknown
- 2008-05-16 PL PL08755799T patent/PL2154969T3/pl unknown
- 2008-05-16 EP EP15190199.8A patent/EP3000320B1/en not_active Not-in-force
- 2008-05-16 AU AU2008254774A patent/AU2008254774B2/en not_active Ceased
- 2008-05-16 MX MX2009012307A patent/MX353727B/es active IP Right Grant
- 2008-05-16 JP JP2010508624A patent/JP5291093B2/ja not_active Expired - Fee Related
- 2008-05-16 US US12/600,141 patent/US8454954B2/en active Active
- 2008-05-16 SI SI200831551T patent/SI2154969T1/sl unknown
- 2008-05-16 DK DK08755799.7T patent/DK2154969T3/en active
- 2008-05-16 ES ES08755799.7T patent/ES2559859T3/es active Active
- 2008-05-16 HU HUE08755799A patent/HUE027278T2/en unknown
2010
- 2010-08-20 HK HK10107964.5A patent/HK1141406A1/zh not_active IP Right Cessation
2013
- 2013-03-01 US US13/782,160 patent/US9101623B2/en active Active
- 2013-06-06 JP JP2013119398A patent/JP2013241411A/ja active Pending
2015
- 2015-08-07 US US14/820,649 patent/US9314512B2/en active Active
- 2015-08-26 HK HK15108265.4A patent/HK1207578A1/xx not_active IP Right Cessation
- 2015-11-17 JP JP2015224428A patent/JP6088027B2/ja not_active Expired - Fee Related
- 2015-12-23 HR HRP20151409TT patent/HRP20151409T1/hr unknown
2016
- 2016-02-16 CY CY20161100131T patent/CY1117312T1/el unknown
- 2016-03-24 US US15/079,709 patent/US10213494B2/en active Active
2017
- 2017-02-02 JP JP2017017216A patent/JP6244486B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MX2009012307A (es)	2010-02-10
EP3000320A1 (en)	2016-03-30
PT2154969E (pt)	2016-02-17
AU2008254774B2 (en)	2013-11-14
CN101754682B (zh)	2014-11-12
US9101623B2 (en)	2015-08-11
US9314512B2 (en)	2016-04-19
HRP20151409T1 (hr)	2016-01-29
US8454954B2 (en)	2013-06-04
WO2008144591A3 (en)	2009-12-30
HUE027278T2 (en)	2016-11-28
EP2154969A4 (en)	2012-08-01
US10213494B2 (en)	2019-02-26
JP5291093B2 (ja)	2013-09-18
JP6244486B2 (ja)	2017-12-06
JP2010535153A (ja)	2010-11-18
EP2154969B1 (en)	2015-11-18
ES2559859T3 (es)	2016-02-16
DK2154969T3 (en)	2016-02-29
AU2008254774A1 (en)	2008-11-27
CN104383556B (zh)	2018-06-05
US20160058849A1 (en)	2016-03-03
CA2684946A1 (en)	2008-11-27
CN104383556A (zh)	2015-03-04
PL2154969T3 (pl)	2016-04-29
CA2684946C (en)	2015-03-31
WO2008144591A2 (en)	2008-11-27
EP3000320B1 (en)	2019-01-16
US20160199461A1 (en)	2016-07-14
EP2154969A2 (en)	2010-02-24
JP2013241411A (ja)	2013-12-05
HK1207578A1 (en)	2016-02-05
SI2154969T1 (sl)	2016-02-29
CN101754682A (zh)	2010-06-23
HK1141406A1 (zh)	2010-11-12
US20110038851A1 (en)	2011-02-17
US20130177549A1 (en)	2013-07-11
JP2016041745A (ja)	2016-03-31
JP6088027B2 (ja)	2017-03-01
JP2017075181A (ja)	2017-04-20
CY1117312T1 (el)	2017-04-26
MX353727B (es)	2017-12-18

Publication	Publication Date	Title
BRPI0811265A2 (pt)	2014-09-30	Tratamento de sinucleinopatias
SMAP200900085A (it)	2010-01-19	3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0910854A2 (pt)	2015-10-06	métodos de tratamento
BRPI0821779A2 (pt)	2019-09-24	tratamento terapêutico de câncer
DE602008004368D1 (de)	2011-02-24	Endoskop-Behandlungswerkzeug
DK2330887T3 (da)	2013-05-21	Behandlingsindretning
BRPI0912683A2 (pt)	2016-01-26	tratamento de tumores metastáticos
BRPI0815551A2 (pt)	2015-02-18	Tratamento através de hucbc de doença beta-amiloide
DK2173831T3 (da)	2012-09-17	Brøndbehandling
DE602008000310D1 (de)	2010-01-07	Endoskopisches Behandlungswerkzeug
BRPI0715728A2 (pt)	2013-09-17	tratamento de distérbio cartilaginosos
DK2501381T3 (da)	2017-11-06	Behandling af atrieflimmer
DK2175849T3 (da)	2013-05-13	Behandling af melanomer
DE602008006133D1 (de)	2011-05-26	Endoskopisches Behandlungswerkzeug
DK2376121T4 (da)	2021-08-16	Slidgigtbehandling
ZA201000225B (en)	2011-03-30	Treatment of depression
EP2184353A4 (en)	2010-09-08	TREATMENT OF INFLUENZA
DK2173197T3 (da)	2019-09-23	Fremgangsmåde
BR112012004071A2 (pt)	2016-03-08	tratamento de petróleo
GB0723100D0 (en)	2008-01-02	Treatment of HFnEF
EP2164494A4 (en)	2010-06-02	Methods of Treatment
BRPI0716580A2 (pt)	2013-10-08	Tratamento de distúrbios fibrosantes
AU2016202705A1 (en)	2016-05-12	Treatment of synucleinopathies
GB0720136D0 (en)	2007-11-28	Treatment of blood disorded
UA14838S (uk)	2007-08-27	Ванна гідромасажна

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-30	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2020-06-09	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-03-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-03-23	B15K	Others concerning applications: alteration of classification	Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/62 Ipc: A61K 48/00 (2006.01), A61K 31/00 (2006.01), A61K 3
2021-03-30	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-04-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 13A ANUIDADE.
2021-08-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.